Micro-organisms administered in the benefit of the host: Myths and facts

European Journal of Gastroenterology and Hepatology

Volumn 12, Issue 10, 2000, Pages 1077-1088

  Marchand, J ^a   Vandenplas, Y ^a  

^a FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

Bacteria; Biotherapeutic agent; Micro organism; Prebiotic; Probiotic; Synbiotic; Yeast

Indexed keywords

PROBIOTIC AGENT;

ARTHRITIS; ARTICLE; ATOPIC DERMATITIS; BIFIDOBACTERIUM BIFIDUM; CLINICAL TRIAL; CROHN DISEASE; DIARRHEA; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; HUMAN; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; LACTOBACILLUS DELBRUECKII; LACTOBACILLUS FERMENTUM; LACTOBACILLUS REUTERI; LACTOBACILLUS RHAMNOSUS; LIVER ABSCESS; MICROFLORA; MICROORGANISM; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; SACCHAROMYCES BOULARDII; STREPTOCOCCUS THERMOPHILUS; WELLBEING;

LACTOBACILLUS RHAMNOSUS; SACCHAROMYCES BOULARDII;

EID: 0033786924     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200012100-00003     Document Type: Article

References (159)

1. Intestinal flora in health and disease
2. Nutritional and metabolic roles of intestinal bacteria
3. Postnatal changes in selected bacterial groups of the pig colonic microflora
4. Diet influences development of the pig (Sus scrofa) intestine during the first 6 hours after birth
5. Antibiotic resistance and the intestinal flora
6. Microbial functional activities
7. Effects of lactulose and lactitol on colonic microflora and enzymatic activity
8. Concept of balanced colonic microbiotica, prebiotics, and synbiotics
9. The application of ecological principles and fermentable fibers to manage the gastrointestinal tract ecosystem
10. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections
11. Survival rate of lactobacilli during digestion. An in vitro study
12. Potential of using tactic acid bacteria for therapy and immunomodulation in man
13. Survie dans l'intestin grele de Lactobacillus acidophilus et Bilidobacterium sp, ingeres dans un lait fermente
14. 'Probiotic' remedies are not what they seem
15. A microbiological investigation on probiotic pharmaceutical products used for human health
16. Antibacterial effect of adhering human Lactobacillus acidophilus strain LB
17. Antagonistic activity exerted in vitro and in vivo by Lactobacillus casei (strain GG) against Salmonella typhimurium C5 infection
18. A controlled clinical study on Streptococcus faecium preparation for the prevention of side reactions during long-term antibiotic treatments
19. Effect of Streptococcus lactic-acid producing bacteria (SF68 strain) on body weight in man: A double-blinded controlled clinical study
20. Alleviation of lactose malabsorption from sweet acidophilus milk
21. Effect of lactic acid bacteria on the intestinal production of lactate and short-chain fatty acids, and the absorption of lactose
22. Viable versus inactivated Lactobacillus strain GG in acute rotavirus diarrhoea
23. Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG
24. Increased bacterial urease activity in faeces in juvenile chronic arthritis: Evidence of altered intestinal microflora?
25. Probiotics: A novel approach in the management of food allergy
26. Suppression of lymphocyte proliferation in vitro by bovine caseins hydrolyzed with Lactobacillus casei GG derived enzymes
27. Do infections protect against atopic diseases?
28. Infections in early childhood and risk of atopic disease
29. The survival of and cytokine induction by tactic acid bacteria after passage through a gastrointestinal model
30. Competitive exclusion of diarrheagenic Escherichia coli ETEC from human enterocyte-like Caco-2 cells by heat-killed Lactobacillus
31. Lactobacillus prophylaxis for diarrhea due to enterotoxigenic Escherichia coli
32. Effect of a lactobacilli preparation on traveller's diarrhea: A randomized double-blind clinical trial
33. A double-blind, placebo-controlled study on the efficacy of Lactinex in the prophylaxis of amoxillin-induced diarrhea
34. Prophylaxis against ampicillin-associated diarrhea with Lactobacillus preparations
35. Diarrhea with enteral feeding: Prospective reappraisal of putative causes
36. Prevention of traveller's diarrhoea. Comparison of different non-antibiotic preparations
37. Lactobacilli to prevent traveler's diarrhea?
38. Traitement des diarrhees aigues chez le nourisson et le jeune enfant 2tude controlee de l'activite antidiarrheique de L. acidophilus tues (souche LB) centre un placebo et un medicament de reference (loperamide)
39. Etude controlee du Lacteol Fort contre placebo et contre produit de reference dans les diarrhees aigues de l'adulte
40. Clinical evaluation of the addition of lyophilized, heat-killed Lactobacillus acidophilus LB to oral rehydration therapy in the treatment of acute diarrhea in children
41. Yoghurt with Bifidobacterium longum reduces erythromycin-induced gastrointestinal effects
42. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis
43. A double-blind trial of non-pathogenic E. coli vs. mesalazine for the treatment of ulcerative colitis
44. Investigation of the stool frequency in elderly who are bed ridden and its improvements by ingestion of bifidus yogurt
45. Complementary medicine in non-ulcer dyspepsia: Is alternative medicine a real alternative? A randomized placebo-controlled double blind clinical trial with two probiotic agents (HYLAC®N and HYLAC®Nforte)
46. Prevention of traveller's diarrhoea by Lactobacillus GG
47. Efficacy of Lactobacillus GG as a diarrhea preventative
48. A human Lactobacillus strain (Lactobacillus casei ssp. strain GG) promotes recovery from acute diarrhea in children
49. Enteral feeding of premature infants with Lactobacillus GG
50. Probiotics in the treatment of irritable bowel syndrome (IBS) - A randomised double bend placebo controlled crossover study
51. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: A multicenter European trial
52. Lactobacillus GG promotes recovery from acute nonbloody diarrhea in Pakistan
53. Effect of Lactobacillus GG yoghurt in prevention of antibiotic associated diarrhoea
54. Lactobacillus GG in the prevention of antibiotic-associated diarrhea in children
55. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG
56. A trial in the Karelian Republic of oral rehydration and Lactobacillus GG for treatment of acute diarrhea
57. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: A randomized study
58. Probiotic treatment of small intestinal bacterial overgrowth by Lactobacillus fermentum KLD
59. Double blind report on the efficacy of lactic acid-producing Enterococcus SF68 in the prevention of antibiotic-associated diarrhoea and in the treatment of acute diarrhoea
60. A double-blind, controlled trial of Bioflorin (Streptococcus faeoium SF68) in adults with acute diarrhea due to Vibrio cholerae and enterotoxigenic Escherichia coli
61. Efficacy of SF 68 in the treatment of acute diarrhea
62. Lactobacillus reuteri as a therapeutic agent in acute diarrhea in young children
63. Bacteriotherapy with Lactobacillus reuteri in rotavirus gastroenteritis
64. Emploi des ferments lactiques dans la gastroenterite non bacterienne
65. Controlled trial of orally administered lactobacilli in acute infantile diarrhea
66. Prophylactic efficacy of lactobacilli on traveler's diarrhea
67. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhea and shedding of rotavirus
68. Prevention of diarrhea by feeding infants with an acidified milk formula containing Bifidobacterium bifidum
69. Reduction of diarrheal illness following administration of Lactobacillus plantarium 299V in a day-care facility [Abstract]
70. Etude controlee du Lacteol Fort sachets versus furazolidine ou berberine dans le traitement des diarrhees aigues de l'enfant
71. Effect of yoghurt on clindamycin-induced Clostridium difficile colitis in hamsters
72. Antibacterial effect of adhering human Lactobacillus acidophilus strain LB
73. Prevention of Helicobacter pylori infection by lactobacilli in a gnotobiotic murine model
74. Impact ecologique de l'antibiotherapie
75. D-Lactic acidosis in children: An unusual metabolic complication of small bowel resection
76. D-Lactic acidosis due to abnormal gut flora
77. D-Lactic acidosis in a man with short-bowel syndrome
78. D-Lactic acidosis after jejunoileal bypass: Identification of organic anions by nuclear magnetic resonance spectroscopy
79. Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis
80. Clinical manifestations and therapy of Lactobacillus endocarditis: Report of a case and review of the literature
81. Chest infection caused by Lactobacillus casei ssp casei
82. Lactobacillus endocarditis caused by probiotic organism
83. Liver abscess due to a Lactobacillus casei indistinguishable from L. casei strain GG
84. Lactobacilli and bacteremia in Southern Finland, 1989-1992
85. Safety of commercial products with viable Lactobacillus strains
86. Lactobacillus casei pneumonia and sepsis in a patient with AIDS. Case report and review of the literature
87. Aortic graft infection by Lactobacillus casei: A case report
88. Safety of lactic acid bacteria and their occurrence in human clinical infection
89. Enterococcal sepsis in neonates: Features, by age at onset and occurrence of focal infection
90. Vancomycin-resistent Enterococcus faecium bacteremia: Risk factors for infection
91. Outbreak of multidrug-resistant Enterococcus faecium with transferable B class vancomycin resistance
92. Nosocemial bacteremia caused by Bacillus species
93. Infections systemiques severes a Bacille cereus: Aspects actuels de la pathogenicite des bacteries du genre Bacillus
94. Vancomycin resistance factor in Lactobacillus casei GG in relation to enterococcal vancomycin resistance (van) genes
95. Use of probiotics in childhood gastrointestinal disorders
96. Use of β-lactamase-producing anaerobes to prevent ceftriaxone from degrading intestinal resistance to colonization
97. Editorial response: What can we de about vancomycin-resistant enterococci?
98. Do bacteria cause chronic polyarthritis?
99. Reverse effect of gram-positive bacteria vs. gram-negative bacteria on adjuvant-induced arthritis in germfree rats
100. Salmonella lipopolysaccharide in synovial cells from patients with reactive arthritis
101. Recovery of Lactobacillus casei GG from human colonic biopsies
102. Saccharomyces boulardii: A review of an innovative biotherapeutic agent
103. Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii in healthy human volunteers
104. Influence of antibiotics on the recovery of Saccharomyces boulardii in rats
105. Bacteria and yeast in the treatment of acute and chronic infectious diarrhoea. II. Yeast
106. Antagonisme in vitro entre Perenterol et differents germes bacteriens
107. In vitro antagonistic effect of Saccharomyces boulardii against bacteria involved in diarrhea in intensive-care-unit patient
108. Inhibitory activity of Saccharomyces yeasts on the adhesion of Entamoeba histolytica trophozoites to human erythrocytes in vitro
109. Saccharomyces boulardii inhibits secretagogue-mediated adenosine 3',5'-cyclic monophosphate induction in intestinal cells
110. Intracellular signal triggered by cholera toxin in Saccharomyces boulardii and Saccharomyces cerevisiae
111. Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum
112. Influence de Saccharomyces boulardii sur la secretion jejunale chez le rat par la toxine cholerique
113. Prevention of Clostridium difficile-induced experimental pseudomembraneous colitis by Saccharomyces boulardii: A scanning electron microscopic and microbiological study
114. Polyamines in human and rat milk influence intestinal cell growth in vitro
115. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa
116. Modulation of Clostridium difficile induced mortality as a function of the dose and the viability of the Saccharomyces boulardii used as a preventive agent in gnotobiotic mice
117. L'effet protecteur de Saccharomyces boulardii sur Escherichia coli enterotoxinogenes (ECET) et enteropathogenes (ECEP): Etude in vitro
118. Biogenic amines as regulators of the proliferative activity of normal and neoplastic intestinal epithelial cells
119. Maturation of villus and crypt cell functions in rat small intestine: Role of dietary polyamines
120. Immunological and tropical effects of Saccharomyces boulardii on the small intestine in healthy human volunteers
121. Polyamines alter intestinal glucose transport
122. Saccharomyces boulardii enhances rat intestinal enzyme expression by endoluminal release of polyamines
123. Saccharomyces boulardii does not stimulate mucosal hyperplasia following intestinal resection in the rat
124. Effects of oral Saccharomyces boulardii on bacterial overgrowth, translocation and intestinal adaptation after small bowel resection in growing rats
125. Saccharomyces boulardii upgrades cellular adaptation after proximal enterectomy in rats
126. Essais cliniques controles en double insu de l'ultra-levure lyophilisee (etude multicentrique par 25 medecins de 388 cas)
127. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: A prospective study
128. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo
129. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients
130. Prevention par Saccharomyces boulardii des diarrhees de l'alimentation enterale a debit continu
131. Interet de Saccharomyces boutardii dans la tolerance digestive de la nutrition enterale a debit continu chez le brule
132. Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients
133. Prophylaxe der reisdiarrhoe mit Saccharomyces boulardii
134. A randomized placebo-controlled trial of Saccharomyces boutardii in combination with standard antibiotics for Clostridium difficile disease
135. Saccharomyces boulardii in acute adult diarrhoea
136. Evaluation therapeutique de Saccharomyces boulardii chez des enfants souffrant de diarrhee aigue
137. Effects of Saccharomyces boulardii in children with chronic diarrhea, especially due to giardiasis
138. Diarrhoen im zusammenhang mit AIDS (doppelblindstudie mit Saccharomyces boulardii)
139. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea - A pilot study
140. Efficacy of two antibiotics and a probiotic in the treatment of small intestinal bacterial overgrowth
141. Traitement des diarrhees aigues infantiles: Essais controle de Saccharomyces boulardii
142. Inhibition of Candida albicans translocation from the gastrointestinal tract of mice by oral administration of Saccharomyces boulardii
143. Uptake of yeast (Saccharomyces boulardii) in normal and rotavirus treated intestine
144. Efficacite de Saccharomyces boulardii dans le traitement des diarrhees du SIDA
145. De deux maux il faut choisir le moindre ou du caractere opportuniste de Saccharomyces boulardii
146. Fongemie a Saccharomyces boulardii
147. Saccharomyces fungemia in AIDS patients after treatment for chronic diarrhea
148. Fungemia with Saccharomyces boulardii in a 1-year-old girl with protracted diarrhea
149. Fongemie a Saccharomyces boulardii chez un brule grave
150. Septicemie a Saccharomyces boulardii apres administration orale d'ultra-levure
151. Are live Saccharomyces yeasts harmful to patients?
152. Fungemia due to Saccharomyces species in a patient treated with enteral Saccharomyces boulardii
153. The ability of probiotic bacteria to bind to human intestinal mucus
154. Probiotics reinforce mucosal degradation of antigens in rats: Implications for therapeutic use of probiotics
155. Probiotics: Established effects and open questions